Supreme Cannabis - Stock (TSX: FIRE) (OTCQX: SPRWF) - Investor Dashboard
|Employees:||>750 as of September 2019|
Supreme Cannabis Co. – Facilities
7ACRES – Kincardine, Ontario
Supreme’s first and primary asset is 7ACRES. 7ACRES is a federally incorporated corporation wholly owned by Supreme. On March 11, 2016, 7ACRES became a Licensed Producer. The Health Canada-approved cultivation facility (the “Facility”) is located in Kincardine, Ontario. Completion of the entire facility is slated for 2019. Once fully operational, 7ACRES is expected to be 440,000 square feet and to have an annual production capacity of 50,000 kilograms.
The Facility is an innovative cultivation platform combining the best aspects of indoor and greenhouse cultivation with a goal to produce premium cannabis flowers for direct consumption. The Facility is designed to provide a platform to produce high quality cannabis at scale, positioning the Company to compete in the premium segment for dried cannabis flowers. Management believes the premium product segment represents a superior opportunity to compete on quality and generate strong contribution margins per gram versus competing in the lower quality product segment of the market.
Management believes high quality cannabis is essential for success and is necessary to combat competition from the black market and low-cost producers. Supreme intends to position 7ACRES as Canada’s leading Business-To-Business (“B2B”) Licensed Producer and leverage its perceived quality advantage by working with multiple re-sellers to capture the premium market segment. Consequently, management is focused on developing and maintaining 7ACRES’ position as a leading The Sureme Cannabis Company, Inc. (Previously Supreme Pharmaceuticals Inc. (Canada) 8528934 Canada Ltd. d/b/a 7ACRES (Ontario) 100% – 4 – Canadian cultivator of premium cannabis flowers at scale. Sales of cannabis are completed via legal and licensed Canadian retailers, which is currently restricted to only Licensed Producers in Canada.
The B2B model is designed to allow 7ACRES to grow its revenue through high value bulk sales while maintaining its focus on cultivation, without the expense of patient acquisition and retention or retail order fulfillment and logistics. Currently, Supreme’s cannabis business is focused on Canada. Supreme is considering opportunities in emerging cannabis markets where medical and/or recreational cannabis is federally legal. Supreme does not, directly or indirectly, have any business operations in jurisdictions where cannabis is not federally legal, such as the United States.
Blissco- Langley, British Columbia
Blissco, acquired by Supreme, has a 12,000-square-foot production facility in Langley, British Columbia. Built to EU GMP standards, the facility gives Supreme in-house extraction capabilities.
The Blissco facility has a cannabis oil extraction lab with a CO2 extractor and ethanol extractor. By the end of 2019, the facility is anticipated to have the annual capacity to produce more than 7 million tincture bottles.
Future expansion plans include the installation of an ethanol extractor, which will support demand for CBD and THC derivative products.
Truverra- Toronto, Ontario
Truverra, acquired by Supreme, has a licensed, 5,000-square-foot research and extraction faclity in Tornto, Ontario. The facility is designed to produce cannabis derivatives. Truverra will serve as Supreme’s global medical brand.
Beyond Canada, Truverra’s wholly owned subsidiary Truverra Europe has a portfolio of hemp-based CBD products.
Cambium- Goderich, Ontario
The 34,000-square-foot Cambium facility is awaiting its cultivation and processing license. It will have up to 500 kilograms of flowre cultivation capacity and an on-site testnig lab. Supreme will use the facility for proprietary R&D.
New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Supreme Pharmaceuticals, Inc. is a client of NCV Media, LLC. Read our full disclaimer.